Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.65 |
| ▸ | CA9 | Q16790 | 5/20 | 0.65 |
| ▸ | STS | P08842 | 8/20 | 0.62 |
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | SHBG | P04278 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599349 | 1.00 | CA2 (0.65) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL14305061 | 1.00 | CA2 (0.65) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL2610034 | 0.90 | CA2 (0.81) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL2617358 | 0.90 | CA2 (0.57) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL2610033 | 0.90 | LMNA (0.72) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL2610030 | 0.90 | CA2 (0.60) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL14599350 | 0.84 | CYP1A2 (0.80) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL2112245 | 0.82 | CYP19A1 (0.59) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL2111077 | 0.82 | SHBG (0.56) | CA2CA9STSESR1CYP3A4 | |
| SCHEMBL2610029 | 0.82 | CYP19A1 (0.59) | CA2CA9STSESR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011005-A2 | ANTIANGIOGENIC AGENTS | ENTREMED, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20070004689-A1 | Antiangiogenic agents | ENTREMED, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004689-A1 | Antiangiogenic agents | VEGFA, FLT4, HDGF | CA2 985/4885CA9 381/4885STS 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.